Aaron Laviana, MD
Urology · Austin, TXNPI 1194016774
Payments from drug & device makers
Across 207 payments — averaging $376.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$69K
- Intuitive Surgical$6K
- Boston Scientific$643
- Teleflex LLC$398
- Johnson & Johnson$253
- Photocure Inc$231
- plus $1K from 11 others
What the payments were for
- Consulting fees$38,32549%
- Speaking & faculty fees$14,40618%
- Grants$390%
- Travel & lodging$12,37216%
- Food & beverage$11,85715%
- Charitable contribution$9051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 147 | $69,360 |
| Intuitive Surgical | 23 | $5,869 |
| Boston Scientific | 11 | $643 |
| Teleflex LLC | 3 | $398 |
| Johnson & Johnson | 3 | $253 |
| Photocure Inc | 2 | $231 |
| Urogen Pharma, Inc. | 2 | $215 |
| KARL Storz Endoscopy-america | 2 | $210 |
| Medtronic | 2 | $173 |
| Koelis Inc. | 1 | $115 |
| Amgen | 1 | $106 |
| Myriad Genetic Laboratories, Inc. | 5 | $78 |
| EDAP Technomed Inc | 1 | $76 |
| Profound Medical Corp. | 1 | $68 |
| Progenics Pharmaceuticals, Inc. | 1 | $65 |
| Telix Pharmaceuticals | 1 | $25 |
| Davol Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLARIX$36,814
- NEOX$4,995
- DA VINCI SP$3,500
- Da Vinci Surgical System$1,986
- Barrigel$254
- Erleada$230
- JELMYTO$184
- INTERSTIM$164
- Cysview$163
- LithoVue$147
- UroLift$144
- FLEX-XC CMOS URETEROSCOPE 8.5 FR X 675MM$133
- SPACEOAR VUE$116
- Trinity 3D Prostate Suite$115
- AKEEGA$106
- XGEVA$106
How this compares
$77,904 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 13 | $34,725 |
| MyrbetriqMirabegron | 28 | $21,053 |
| Abiraterone Acetate | 14 | $1,821 |
| Tamsulosin Hcl | 83 | $1,119 |
| Cephalexin | 22 | $361 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $197 |
| Finasteride | 23 | $186 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $137 |
| Prednisone | 17 | $83 |
Paid to pharmacies, not to this prescriber.
Other urology in Austin
- Michael TrotterAustin$892K
- Varun SundaramAustin$400K
- Elizabeth MobleyAustin$283K
- Parviz KavoussiAustin$251K
- Peter RuffAustin$168K
- Zvi SchiffmanHouston$17.8M
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Jose KaramHouston$5.7M
- Daniel ZainfeldSan Antonio$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.